Cofactor Genomics, a leader in cancer immunotherapy predictive diagnostics, today announced results from the PREDAPT ...

Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...

Jonathan Thompson, MD, MS, emphasized that comprehensive biomarker testing with next-generation sequencing and PD-L1 analysis—implemented as reflex testing at biopsy—is essential to guide precision ...

Perioperative immunotherapy for stage II-III NSCLC patients: A retrospective real-world analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a ...

GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving. Delays in molecular testing for ...